Korro Bio, Inc. (KRRO NASDAQ) stock market data APIs
$12.5696
0.7(5.6%)
as of May 5, 2026
Try our APIs with
free plan!
Korro Bio, Inc. Financial Data Overview
Price chart is built with
Anychart
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Prev. Close
12.5696
Open
13.2705
High
13.3394
Low
12.1675
52 wk Range
5.2044-55.89
Market Cap
188 M
Shares Outstanding
14 423 K
Revenue
6 392 K
EPS
-1.6472
Beta
2.228
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Korro Bio, Inc. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Korro Bio, Inc. data using free add-ons & libraries
Get Korro Bio, Inc. Fundamental Data
Korro Bio, Inc. Fundamental data includes:
- Net Revenue: 6 392 K
- EBITDA: -83 062 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-13
- EPS/Forecast: -2.1375
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Korro Bio, Inc. News
New
Top 5 Insider Buys From Q1: Buy, Sell, or Hold in Q2?
Colorful stock market chart with rising and falling lines behind bold “Insider Trades” text, symbolizing investor activity and insider buying trends. Key Points Insiders were active in Q1, but i...
Friday 3/13 Insider Buying Report: LOAR, KRRO
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their har...
Korro Bio, Inc. (KRRO) Reports Q4 Loss, Lags Revenue Estimates
Korro Bio, Inc. (KRRO) came out with a quarterly loss of $5.32 per share versus the Zacks Consensus Estimate of a loss of $1.93. This compares to a loss of $2.26 per share a year ago. These figures ar...
United Therapeutics (UTHR) Surges 10.7%: Is This an Indication of Further Gains?
United Therapeutics UTHR shares rallied 10.7% in the last trading session to close at $529.17. This move can be attributable to notable volume with a higher number of shares being traded than in a typ...
Get Korro Bio, Inc. fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
